Related Experiment Videos
SYT-SSX fusion proteins in synovial sarcomas: detection and characterization with new antibodies
N Hashimoto1, N Araki, H Yoshikawa
1Department of Orthopedic Surgery, Osaka University Medical School, Suita, Japan.
Abstract:
To identify and characterize the SYT-SSX fusion proteins in synovial sarcomas, we developed two polyclonal antibodies against the N-terminal part and for the C-terminal part of the SYT-SSX2 protein. Specificity was demonstrated on COS-7 cells transfected with two subtypes of SYT-SSX fusion genes, SYT-SSX1 and SYT-SSX2. Both antibodies recognized a single protein of 61 kDa in an immunoprecipitation of the transfected COS-7 cell lysates. These antibodies also detected the native protein of 61 kDa in the lysate of a human synovial sarcoma cell line (HS-SY41) with immunoprecipitation, and in extracts of human synovial sarcomas with western blot analysis. An immunohistochemical study, using human synovial sarcoma tissues, demonstrated that the SYT-SSX fusion proteins localized in the nucleus of the tumor cells. These antibodies provide a useful method for studying the expression of the SYT-SSX fusion proteins.
Insights
Researchers developed novel antibodies to detect SYT-SSX fusion proteins, crucial biomarkers in synovial sarcoma. These tools enable accurate identification and characterization of these oncoproteins in tumor cells.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Synovial sarcoma is characterized by specific chromosomal translocations resulting in fusion genes, such as SYT-SSX1 and SYT-SSX2.
- SYT-SSX fusion proteins are considered key oncogenic drivers in the pathogenesis of synovial sarcoma.
- Accurate detection and characterization of these fusion proteins are essential for understanding disease mechanisms and developing targeted therapies.
Purpose of the Study:
- To develop and validate polyclonal antibodies for the specific identification and characterization of SYT-SSX fusion proteins.
- To assess the utility of these antibodies in detecting native SYT-SSX proteins in cell lines and tumor tissues.
- To investigate the subcellular localization of SYT-SSX fusion proteins within synovial sarcoma cells.
Main Methods:
- Development of two polyclonal antibodies targeting the N-terminal and C-terminal regions of SYT-SSX2.
- Testing antibody specificity using COS-7 cells transfected with SYT-SSX1 and SYT-SSX2 fusion genes.
- Immunoprecipitation assays to detect SYT-SSX proteins in transfected cells and a human synovial sarcoma cell line (HS-SY41).
- Western blot analysis of human synovial sarcoma tissue extracts.
- Immunohistochemical staining of human synovial sarcoma tissues.
Main Results:
- Both developed antibodies specifically recognized a single 61 kDa protein in immunoprecipitation assays of transfected cells.
- The antibodies successfully detected the native 61 kDa SYT-SSX protein in a human synovial sarcoma cell line lysate and tumor extracts.
- Immunohistochemical analysis revealed that SYT-SSX fusion proteins are localized within the nucleus of synovial sarcoma tumor cells.
- The antibodies demonstrated high specificity and sensitivity for detecting SYT-SSX fusion proteins.
Conclusions:
- The novel polyclonal antibodies are effective tools for the specific detection and characterization of SYT-SSX fusion proteins.
- These antibodies facilitate the study of SYT-SSX fusion protein expression in synovial sarcoma.
- The findings confirm the nuclear localization of SYT-SSX fusion proteins, providing insights into their oncogenic function.